Ulcusan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ulcusan

Quick Facts

Property Description
Active ingredient Famotidine
Form Oral tablet, Oral suspension, IV solution
Pharmacological class Histamine H₂-receptor antagonist (H₂ blocker)
Common action Reducing gastric acid secretion
Origin Synthetic small molecule

Ulcusan is a medicine whose active ingredient is Famotidine, a substance primarily used to control and decrease the amount of acid produced by the stomach. It is classified pharmacologically as a Histamine H₂-receptor antagonist, commonly known as an H₂ blocker. This drug is a synthetic small molecule designed to precisely inhibit the chemical signals that trigger acid secretion.


What Type of Medicine is Ulcusan?

Ulcusan belongs to the H₂ blocker class, a group of agents that provide a significant and sustained antisecretory effect by blocking specific histamine receptors on the stomach’s lining cells. This action prevents the natural chemical messenger, histamine, from signaling the cells to create acid. This mechanism is clinically recognized for its reliable control over gastric acid output, characterized by the high selectivity of Famotidine for the H₂ receptor. The medicine is available for oral intake, typically as a tablet, though an intravenous solution also exists for use in more urgent clinical settings.


How Does Ulcusan’s Composition Relate to its Use?

The medicine is composed of the single active substance Famotidine, which contains a unique guanidine-substituted thiazole ring, giving the compound the formula C8H15N7O2S3. It is formulated in various dosage forms, including tablets and suspensions. This consistent composition enables the drug to fulfill its general purpose: to consistently alleviate discomfort and irritation. By maintaining a less acidic internal environment, the drug supports the body's natural ability to allow the sensitive tissues of the upper gastrointestinal tract to heal and recover from the corrosive effects of excessive gastric fluid.

Regulatory References

  1. StatPearls - NIH

What side effects are possible with Ulcusan?

Possible Side Effects and Safety Information

The safety profile for Ulcusan (Famotidine) is formally structured and classified by governmental health authorities based on the frequency and the specific system-organ classes (SOC) affected. This information is critical for understanding the established risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by how often they appeared in clinical studies. Common reactions, defined in regulatory documents as those occurring in more than 1 in 100 but less than 1 in 10 patients, include Headache, Dizziness, Constipation, and Diarrhea. Less frequent effects classified as Uncommon include dry mouth, nausea, vomiting, and fatigue. Rare reactions have also been documented, such as joint pain (Arthralgia).

System-Organ Classes and Serious Events

Side effects are mapped to major physiological systems. Most commonly reported adverse events fall under Gastrointestinal disorders and Nervous system disorders. The regulatory labels also specify Serious Adverse Reactions, which are typically rare but clinically significant. These include severe hypersensitivity reactions (such as anaphylaxis and angioedema), severe cutaneous adverse reactions (SCARs), and cardiac arrhythmias (e.g., QT prolongation), particularly noted with the intravenous formulation.

Population-Specific Safety Notes

Specific safety considerations are noted for certain patient groups. For Older Adults and those with Renal Impairment, official labeling indicates an increased risk for central nervous system (CNS) adverse reactions, such as confusion or hallucinations. This risk is dose-dependent and is a key focus of safety monitoring in these populations. Famotidine is also documented as being secreted via breast milk.

Overdose and Emergency Response

Overdose: When to Seek Medical Help

Official data on acute overdose with Famotidine (the active ingredient in Ulcusan) is limited. In cases where overdose has occurred, documented presentations suggest that signs and symptoms would be an exaggeration of the drug’s known adverse effects.

Overdose risk is particularly relevant to patients with pre-existing conditions affecting drug clearance:

  • Population-Specific Risk: Elderly patients and individuals with moderate or severe renal impairment may experience higher blood concentrations of the drug due to slower elimination. This increased exposure raises the risk of Central Nervous System (CNS) adverse reactions.
  • Potential CNS Effects: These reactions, which may be exacerbated in an overdose scenario, can include confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy.

Required Emergency Actions

If an overdose is suspected or has occurred, immediate medical attention is necessary. Regulatory instructions are clear:

  • Seek medical help or contact a Poison Control Center right away.
  • Management of overdose typically involves supportive therapy, clinical monitoring, and removal of any unabsorbed material from the gastrointestinal tract.

Therapeutic Uses of Ulcusan

Easing Acute Symptoms of Gastrointestinal Discomfort

Famotidine may be applied across domains where additional symptomatic support is needed, particularly for symptoms related to physical discomfort and heightened physiological activity in the upper gastrointestinal system. The medicine is relevant in contexts involving symptoms that create noticeable physiological strain. It is commonly used when patients need short-term symptomatic assistance for easing the overall symptom load during acute phases, such as those related to conditions involving inflammatory or irritative processes.


Managing Recurrent or Episodic Condition Patterns

This medication is relevant in contexts marked by increased discomfort or tension, such as in conditions characterized by periods of heightened symptoms or episodic or fluctuating manifestations. Ulcusan is commonly used to help with symptom clusters that may become temporarily overwhelming. It may be part of symptomatic management, supporting short-term symptom stabilization during difficult episodes. It contributes to easing the overall symptom load when symptoms unexpectedly become noticeable.

Quick Fact: May provide support for Stomach Discomfort


Supporting General Comfort and Functional Stability

Ulcusan supports general well-being during symptomatic phases. By providing supportive relief when symptoms interfere with routine activities, it may assist with maintaining functional stability. This symptomatic relief may help patients cope more steadily with temporary functional strain.

Eligibility and Restrictions for Use

Ulcusan, which contains the active ingredient famotidine, is a commonly prescribed H2 blocker used to treat and prevent various gastrointestinal conditions, including peptic ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome.

Who Can Use Famotidine?

Famotidine is generally safe for use in most adults and children, often available both over-the-counter (OTC) at lower doses for heartburn relief and by prescription for more chronic or severe conditions. It is used to:

  • Treat active duodenal and gastric ulcers.
  • Manage GERD and erosive esophagitis.
  • Reduce gastric acid secretion in conditions like Zollinger-Ellison syndrome.
  • Prevent heartburn or acid indigestion.

Who Should Not Use Famotidine?

Famotidine is contraindicated or requires caution in specific patient populations. You should avoid famotidine if you have a known allergy or hypersensitivity to famotidine or other H2 receptor antagonists (such as cimetidine or ranitidine).

Caution is advised for individuals with pre-existing conditions, particularly:

  • Kidney problems or severe renal impairment, as famotidine is primarily excreted by the kidneys and dosage adjustments may be necessary.
  • Liver disease.
  • Difficulty swallowing or persistent chest pain, as these symptoms may indicate a more serious condition.

Pregnant or breastfeeding women should consult a healthcare provider before use to weigh the potential risks and benefits. While it is generally considered safe, use should be monitored.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Famotidine's official interaction profile is structured around two primary pharmacokinetic risk domains: alteration of gastric acidity and interference with drug clearance pathways.


Exposure-Altering Interactions (Gastric pH)

Famotidine, by reducing gastric acid, is documented to significantly reduce the systemic exposure of co-administered drugs that require an acidic environment for proper absorption. This includes medicinal products such as the antifungals Ketoconazole and Itraconazole, as well as certain HIV agents (e.g., Atazanavir) and some cancer agents (e.g., Erlotinib and Dasatinib). Loss of efficacy for the co-administered drug is the formal concern.

Clearance Pathway Restrictions

Co-administration of Famotidine with Tizanidine is restricted in regulatory labeling, as Famotidine is documented to inhibit the CYP1A2 enzyme pathway, leading to a potential for substantial increases in Tizanidine blood concentrations. Similarly, co-administration with Probenecid is advised to be avoided, as Probenecid inhibits the renal tubular secretion of Famotidine, resulting in a documented increase in Famotidine plasma exposure.


Mandatory Administration Timing and Population Notes

Interaction Entity Timing/Restriction Rule (from Regulatory Documents)
Sucralfate Must not be administered within two hours of Famotidine.
Antacids Should be administered one to two hours before Famotidine.
Renal Impairment Dosage reduction is formally required for patients with creatinine clearance <30 mL/min due to the risk of systemic accumulation.
Food/Alcohol No clinically significant interaction with food or alcohol is documented.

Mechanism of Action

How Ulcusan (Famotidine) Works

The action of Famotidine is focused on modifying the body's gastric acid secretion system by regulating processes driven by specific chemical signaling.

H2 Receptor Antagonism and Signal Suppression

Famotidine acts as a competitive antagonist of the Histamine-2 (H2) receptors found on the basolateral membrane of stomach parietal cells. By binding to these sites, the drug prevents the endogenous messenger histamine from attaching and suppresses the normal intracellular signaling cascade that histamine would otherwise initiate.

Modulating the Acid Secretion Pathway

The blockage of the H2 receptor limits the subsequent pathway activation within the parietal cell, resulting in reduced function of the proton pump ( H^+/ K^+-ATPase). This cascade modification leads directly to a decrease in the volume and concentration of secreted hydrochloric acid ( HCl) in the stomach.

Resulting Reduction in Gastric Acidity

By suppressing this pathway, the mechanism achieves a reduction in acid output, specifically inhibiting the basal (resting) acid secretion. This physiological consequence leads to a rise in gastric pH, altering the chemical environment within the stomach.

Dosage and Administration Information

Ulcusan, with the active substance Famotidine, is administered through two approved routes: the oral route via tablets or a reconstituted suspension, and the intravenous (IV) route, which is generally reserved for short-term use in clinical settings for patients unable to tolerate oral intake. The oral tablets may be taken with or without food, and the timing is standardized for effectiveness, often taken once daily at bedtime for maintenance or 40 mg acute dosing. Twice-daily regimens typically use 20 mg doses.

Standard dosing for acute conditions like ulcers is typically prescribed for a short-term course, such as 4 to 8 weeks, whereas use for recurrence prevention may involve a long-term maintenance plan. Over-the-counter use of the lower strength tablets is strictly limited to a 14-day maximum duration.

For IV administration, the 20 mg dose is given every 12 hours. Procedurally, the solution must be appropriately diluted for infusion or administered slowly over at least two minutes as a direct injection. A mandatory procedural instruction is the required dose adjustment for renal impairment: for patients with reduced kidney function (creatinine clearance below 50 mL/min), the dosage must be reduced or the interval extended to 36 to 48 hours. If a dose is missed, it should not be doubled, and the patient should resume the regular schedule.

Recent Clinical Evidence

Overview of Clinical Research

Famotidine is a histamine-2 (H2) receptor antagonist, a type of medicine widely studied for its ability to reduce gastric acid secretion. Clinical trials primarily focus on its use in conditions related to excess stomach acid, including gastric and duodenal ulcers, symptomatic nonerosive gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions like Zollinger-Ellison syndrome.

Research has explored the effects of both over-the-counter and prescription formulations in various patient populations, with key findings centered on its speed of action and sustained effect on acid suppression.


Key Study Findings and Research Scope

Phase 3 Randomized Controlled Trials (RCTs) typically assess outcome measures such as the healing rate of ulcers or observed changes in patient-reported symptom scores compared to placebo. Studies note that the onset of acid suppression occurs within the first hour after oral administration, with peak effects generally reached within one to three hours. The duration of effect on acid secretion is typically sustained for 10 to 12 hours.

Specific research has investigated the drug's properties in combination with other therapeutic agents, such as for the eradication of Helicobacter pylori bacteria, although other treatments may show slightly higher efficacy in this role.


Special Populations and Safety Profile Research

Research has explored the effects and collected tolerability data for famotidine in pediatric and elderly populations. Studies indicate that older adult patients may require focused monitoring, especially if they have existing age-related kidney function changes, as the drug's elimination half-life can increase substantially with renal impairment. Studies have linked poor kidney function to an elevated risk of central nervous system (CNS) adverse reactions, necessitating dose adjustments as dictated by a healthcare professional.

Population Studied Research Focus Key Observation
Elderly Effects with renal impairment Increased half-life may necessitate dose adjustment.
Pediatric Safety and tolerability Generally well-tolerated; specific dosing based on weight.

Ongoing clinical research has also expanded into off-label areas, including the exploration of famotidine's role in inflammatory conditions, such as those associated with COVID-19, though evidence remains limited and is not considered conclusive.

Frequently Asked Questions (FAQ)

Common questions about Ulcusan (Famotidine) (FAQ)


Q: How fast does Ulcusan usually start working for stomach acid?

A: According to official regulatory documents, the effect of Ulcusan on reducing acid secretion typically begins within one hour after it is taken orally. The maximum acid-reducing effect is usually seen within one to three hours. This quick onset is a key characteristic of its action on symptoms of excess stomach acid.


Q: Is it safe to take Ulcusan with common pain relievers like ibuprofen?

A: Some prescription products combine Famotidine with ibuprofen to help protect the stomach lining from potential side effects caused by the pain reliever. However, official drug information for single-ingredient Famotidine does not specifically detail interactions with all over-the-counter pain relievers. It is important to consult with a healthcare professional when considering taking them together.


Q: Does Ulcusan treat the symptoms or does it actually heal the stomach lining?

A: Ulcusan is prescribed to treat conditions such as ulcers and erosive esophagitis, which involve damage to the stomach lining. Its primary function is to significantly reduce the amount of acid produced, which then creates a favorable environment that facilitates the body’s natural healing process for these damaged tissues. Clinical trials assess the effectiveness based on both the healing rate of ulcers and the reduction of symptoms.


Q: Is it normal to feel a bit dizzy after taking Ulcusan?

A: Official information from regulatory bodies lists dizziness as one of the commonly reported side effects observed in patients during clinical studies. If dizziness or any other side effects occur, it is advisable to discuss these with a healthcare professional.


Q: Does Ulcusan cause drowsiness?

A: Unusual drowsiness, or somnolence, is listed as a rare or very rare adverse reaction in the drug's safety profile. This effect is seen more frequently in patients who have pre-existing kidney problems. Individuals should be aware of how the medicine may affect them, especially when engaging in activities that require full mental alertness.


Q: Is Ulcusan safe for older adults (seniors)?

A: Famotidine has been researched for use in the elderly population. Official safety information indicates that older adults may have an increased risk of central nervous system (CNS) adverse reactions like confusion. The potential need for dose adjustments is a consideration for older adults, particularly those with reduced kidney function.


Q: What happens if I forget to take my Ulcusan dose?

A: According to official guidelines, if a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Patients are cautioned against doubling up or taking two doses at the same time to compensate for a missed dose.


Q: Why do some people take Famotidine before eating?

A: For the purpose of preventing expected heartburn or acid indigestion, the lower-strength, over-the-counter dosage is often instructed to be taken proactively. Official drug data supports taking it approximately 10 to 60 minutes before eating food or drinking beverages that are known to trigger acid symptoms. This timing aligns with the drug's onset of action.


Q: Can Ulcusan affect the absorption of other oral medications?

A: Yes, regulatory documents indicate that Ulcusan can affect how the body absorbs certain other medicines. By significantly decreasing stomach acid, Famotidine can reduce the systemic exposure of drugs that require an acidic environment to dissolve and be properly absorbed into the bloodstream. It is advisable to review all current medications with a healthcare professional to check for potential interactions.


Q: Is Ulcusan the same kind of medicine as Tums or Rolaids?

A: No, they belong to different classes of medication. Ulcusan is a Histamine H₂-receptor antagonist (H₂ blocker), which works by actively preventing the cells in the stomach from producing acid. Antacids (like Tums or Rolaids) are neutralizing agents that work by directly buffering existing acid and are in a different drug class. They can be taken alongside Ulcusan, but often require a specific time delay.


Q: Does Ulcusan help with acid reflux at night?

A: Studies included in the official drug information confirm that single doses taken in the evening were effective at inhibiting nocturnal acid secretion for at least ten hours. By raising the pH level in the stomach, Ulcusan can provide sustained relief throughout the night.


Q: Can Ulcusan cause any long-term side effects?

A: Official drug labels state that studies have been conducted on long-term use for preventing acid recurrence. While Famotidine is generally well-tolerated, rare serious effects, including potential CNS effects, have been reported. Continuous use is typically monitored by a healthcare provider to assess the risk-benefit balance over time.


Q: Will Ulcusan stop working if I take it every day?

A: Clinical data indicates there was no cumulative effect with repeated daily doses, suggesting the drug’s performance should remain consistent. However, some non-regulatory research has suggested that the body's acid-suppressing response may diminish slightly over time with continuous use, a concept sometimes referred to as tolerance.


Q: What are the known severe, but rare, side effects of Ulcusan?

A: Official post-marketing reports list severe, but rare, adverse reactions. These include life-threatening hypersensitivity reactions (like anaphylaxis), severe skin reactions, and changes to heart rhythm such as QT prolongation. Due to their serious nature, these rare events warrant prompt medical evaluation if they occur.


Q: Does the brand name Ulcusan differ from generic Famotidine?

A: In most regulated regions, generic Famotidine products are classified by government agencies as being bioequivalent and therapeutically equivalent to the original brand name product. This means the generic version is expected to work in the same way and provide the same clinical benefit as Ulcusan.


Q: Does Ulcusan work better in the morning or at night?

A: Studies show that the timing depends on the symptoms being targeted. Doses taken in the evening are highly effective at suppressing nocturnal acid secretion (acid produced during sleep), while morning doses suppress food-stimulated acid secretion (daytime acid). The optimal schedule is typically determined by a healthcare provider based on the patient's specific symptoms and needs.


Q: Is it possible to develop a tolerance to the effects of Ulcusan?

A: While regulatory data indicates there was no cumulative effect from repeated daily doses, some external studies have suggested that the acid-suppressing effects may lessen over time with continuous use. If the medication is perceived as becoming less effective, consultation with a healthcare provider is recommended.


Q: Can Ulcusan affect my mood or cause anxiety?

A: The drug label lists several rare psychiatric adverse reactions, including anxiety, agitation, and depression. Although these are not common, they are documented effects, especially in older adults or those with renal impairment. These effects are typically reversible after stopping the medication.


Q: What are the ingredients in Ulcusan other than the active drug Famotidine?

A: Famotidine is the sole active ingredient. However, official drug labels also list inactive ingredients or excipients, such as microcrystalline cellulose, corn starch, and various binding agents and colorants, which are necessary to form the tablet or suspension. The exact list can vary by the specific product formulation.


Q: How long does it take to see the full benefit of Ulcusan for persistent acid reflux?

A: While the acid suppression begins quickly (within one hour), achieving the full clinical benefit for persistent conditions like erosive esophagitis takes time. Clinical studies often observe significant symptomatic relief and healing over a period of two to six weeks, with treatment courses sometimes lasting up to 12 weeks.


Q: What are the signs that Ulcusan isn't working for my symptoms?

A: If over-the-counter symptoms like heartburn or sour stomach last longer than two weeks, official information advises consulting a healthcare provider. Also, if you experience new, serious symptoms such as unexplained weight loss or persistent abdominal pain, such symptoms warrant consultation with a healthcare professional.


Q: Does Ulcusan help with gas or just acid?

A: Ulcusan is formally indicated for conditions related to excessive gastric acid secretion. The official drug label lists flatulence (gas) as an uncommon side effect. However, the medicine is not generally prescribed or indicated as a dedicated treatment for bloating or gas.

How should Ulcusan be stored and disposed of?

Official Storage and Disposal Profile

Famotidine (Ulcusan) must be stored and disposed of according to strict regulatory guidelines to maintain its stability and ensure public safety.

Storage Requirements

Condition Type Requirement Summary
Temperature Famotidine tablets are generally stored below 25 C or at room temperature. The liquid formulation (Oral Suspension) must not be allowed to freeze.
Protection Keep the medication in its tightly closed, original container and protect it from both light and moisture. Do not store in the bathroom due to excess heat and moisture.

Stability and Handling

Once the Famotidine Oral Suspension is constituted (mixed), any unused portion must be discarded after 30 days. All forms of Famotidine must be kept out of sight and reach of children and stored in a safe location with safety caps locked.

Disposal Instructions

Any unused or expired Famotidine product must be disposed of in accordance with local requirements. Patients should consult a healthcare professional or local waste disposal service for guidance on the proper disposal of outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulcusan found in:

A-Z Index: